Search

Introduction: According to UNICEF, 2 million children have left the country since the beginning of the war. 2.5 million Ukrainian children are internally displaced persons. Minors often become victims or witnesses of violence. The events of 2022-2023 are the largest military conflict in the world since World War II. The impact on the mental health of the population is characterized by the variety and mass of traumatizing factors. Mental trauma causes PTSD, depressive disorders (DD), anxiety disorders (AD), behavioral disorders (CD), attention deficit hyperactivity disorder (ADHD). Objectives: The aim of the study was to determine the prevalence of PTSD and its comorbidities at different stages of experiencing a traumatic experience. Methods: 785 teen's displaced from the zone of military operations, occupied territories were surveyed. Examinations included: K-SADS-PL, PSC-17, SCARED, CATS. 260 teen's were examined during - 6, 400 – 6–12 months after traumatization. Results: After 6 months of trauma, PTSD was diagnosed in 9.8%, ADHD – 10.2%, DD-22.3%, AD-30.8%, CD – 15.4%, 28.8%; examined 6 to 12 months after the injury, respectively: 21.9%, 12.6, 33.3%, 11.5%, 18.0%. Conclusions: In war-affected children, PTSD is a risk factor for the subsequent development of comorbid depression, anxiety, conduct disorders, and ADHD. Female sex, secondary traumatization after displacement increase the risk of developing depression, signs of pervasive development and ADHD - the risk of destructive and self-injurious behavior. The prevalence of PTSD, DD, ADHD increases within 6-12 months after the trauma, the sensitivity of children with PTSD to secondary traumatic events increases. Disclosure of Interest: None Declared [ABSTRACT FROM AUTHOR]

Introduction: Clinical comorbidity ASD, tics disorders and epilepsy can be determined by different variants of genetic polymorphism, as an option different variants of gene expression, determined by different environmental influences. Objectives: The purpose of the study was to study the features of the clinical phenotype of ASD in preschool and school-age children with tics, epileptic seizures and specific epileptic activity on EEG. Methods: 116 children aged 2-10 years with ASD were examined. For diagnostics, ADI-R, ADOS techniques and DSM-V diagnostic criteria were used. DAWBA was used to screen for comorbid disorders. The study group was divided into three subgroups: subgroup A - 23 children with a history of epileptic seizures, subgroup B - 35 children with specific forms of epileptic activity on EEG without epileptic seizures, subgroup C - 19 children with ASD having specific epileptic activity for EEG repetitive involuntary movements (motor and vocal tics). The control group consisted of 39 children with ASD none a history of seizures and specific epileptic activity on the EEG. The follow-up of children with ASD in the comparison groups was performed for 3-5 years. Results: Clinical phenotypes of ASD with epileptic seizures or specific epileptic activity on the EEG are characterized by differing clinical symptoms and their change during follow-up. Motor and vocal tics were present in subgroup C (P < 0,001); no differences were found in subgroups A and B. Conclusions: Further research is needed on the clinical phenotypes of ASD polymorbid disorders. [ABSTRACT FROM AUTHOR]

Introduction: Efficacy and safety of Levetiracetam and Risperidone for aggression irritability, and hyperactivity in adolescent with autism spectrum disorder (ASD) are controversial Objectives: The sudy of Levetiracetam and Risperidone efficacy and safety for aggression and mood instability in ASD adolescents. Methods: 66 adolescents with ASD (MD = 14,6) were randomized into three groups: Lvetiracetam + Risperidone (A), Placebo + Risperidone(B) and Placebo +Levetiracetam (C) for an 8-week, placebo-controlled study with the use of flexible doses of Risperidone (1.0-3.0 mg; MD = 2,3) and LCT(1000.0 - 2000.0 mg; MD = 1580 mg). Patients were assessed at baseline and after 2, 4, 6 and 8 weeks of therapy. We used: DAYS, MASC, LSAS-CA, YBOCS, ADHD-IV, SCQ, ASDS, RAASI, SSRS, GAF. Groups were considered the independent variable, and five measurements during treatment were considered as the dependent variable for themultiple regression analysis. Results: Compared with the group B, patients of group C demonstrated improved symptoms of hyperactivity, impulsivity and mood instability. No treatment difference was observed between A and B groups for the SCQ, ASDS, RAASI and SSRS. Changes in groupAwere greater than in C and B. The GAF score in the patients improved significantly from 39.00±7.36 before therapy to 58.00± 9.12 after risperidone (F = 30.16, df = 1, p < 0.001) and to 64.00 ± 8.21 after Levetiracetam + Risperidone (F = 33.89, df = 1, p < 0.001). Conclusions: Risperidone is useful in treating behavioral problems; adding Levetiracetam to Risperidone was more effective for irritability and stereotyped behavior. [ABSTRACT FROM AUTHOR]